glutathione drug release responsive nanomedicine leverages tumor redox imbalance for targeted cancer theranostics | Discover Oncology A glutathione-activated carrier-free nanodrug of

We focus on understanding how pathogens persist outside the host, move between environmental reservoirs and production settings, and acquire traits that influence persistence and survival

Dunbar E, Coats B, Shroads A, Langaee T, Lew A, Forder J, et al

and the 2025 Monitoring Program, which includes substances that are not on the List, but that WADA wishes to monitor in order to detect potential patterns of misuse in sport

Ferguson LR, Browning BL, Huebner C, Petermann I, Shelling AN, Demmers P, McCulloch A, Gearry RB, Barclay ML, Philpott M: Single nucleotide polymorphisms in human Paneth cell defensin A5 may confer susceptibility to inflammatory bowel disease in a New Zealand Caucasian population